journal article·2026-01

Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles

Yi Lin, Mengyao Li, Zijin Luo, Yanan Meng, Yan Zong, Hongyu Ren, Xiaolu Yu, Xiaoqiong Tan, Fan Liu, Tuo Wei, Qiang Cheng

Nature Materials· Volume 25· Issue 1
Publisher page

Abstract

Lipid nanoparticles for mRNA delivery and gene editing have the potential to transform the current therapeutic landscape. Nonetheless, a major bottleneck using this technology is the difficulty in achieving cell- and tissue-specific delivery and avoiding liver accumulation. Here we report the rational design of peptide ionizable lipids to assemble lipid nanoparticles with organ-selective mRNA delivery. Structure-activity and structure-selectivity relationship analyses enable us to obtain a general and predictable strategy for peptide ionizable lipid design. By incorporating artificial ionizable and natural amino acids and/or functional molecules into peptide ionizable lipids, we create lipid nanoparticles with tissue-specific targeting, including the lungs, liver, spleen, thymus and bone. In particular, lipid nanoparticles containing peptide lipids targeting the liver show comparable efficacy and safety compared with FDA-approved formulations. Furthermore, lipid nanoparticles with peptide lipids achieve the efficient co-delivery of PEmax mRNA and engineered prime editing guide RNA for prime editing of the liver and lungs. Overall, our platform offers a predictable methodology for the rational design of tissue-targeting lipid nanoparticles that might aid the development of improved mRNA-based gene editing therapeutics.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · CRISPR and Genetic Engineering · RNA regulation and disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709–722 (2024).10.1038/s41573-024-00977-6 ↗
2. Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630–643 (2021).10.1038/s41565-021-00898-0 ↗
3. Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Primers 3, 63 (2023).10.1038/s43586-023-00246-7 ↗
4. Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).10.1038/mt.2010.85 ↗
5. Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A. & Sahay, G. Strategies for non-viral vectors targeting organs beyond the liver. Nat. Nanotechnol. 19, 428–447 (2024).10.1038/s41565-023-01563-4 ↗
6. Herrera-Barrera, M. et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci. Adv. 9, eadd4623 (2023).10.1126/sciadv.add4623 ↗
7. Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13, 214–219 (2018).10.1038/s41565-017-0043-5 ↗
8. Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).10.1126/science.abm0594 ↗
9. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
10. Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).10.1038/s41565-024-01680-8 ↗
11. Han, X. et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat. Commun. 14, 75 (2023).10.1038/s41467-022-35637-z ↗
12. Lei, J. et al. Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability. Angew. Chem. Int. Ed. 63, e202318515 (2024).10.1002/anie.202318515 ↗
13. Gautam, M. et al. Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nat. Commun. 14, 6468 (2023).10.1038/s41467-023-42189-3 ↗
14. Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).10.1126/sciadv.ade1444 ↗
15. Abd Elwakil, M. M. et al. Harnessing topology and stereochemistry of glycidylamine-derived lipid nanoparticles for in vivo mRNA delivery to immune cells in spleen and their application for cancer vaccination. Adv. Funct. Mater. 33, 2303795 (2023).10.1002/adfm.202303795 ↗
16. Zhang, R. et al. Esterase-labile quaternium lipidoid enabling improved mRNA-LNP stability and spleen-selective mRNA transfection. Adv. Mater. 35, 2303614 (2023).10.1002/adma.202303614 ↗
17. Chen, J. et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc. Natl Acad. Sci. USA 120, e2309472120 (2023).10.1073/pnas.2309472120 ↗
18. Li, Z. et al. Enzyme-catalyzed one-step synthesis of ionizable cationic lipids for lipid nanoparticle-based mRNA COVID-19 vaccines. ACS Nano 16, 18936–18950 (2022).10.1021/acsnano.2c07822 ↗
19. Han, X. et al. Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. Nat. Chem. 16, 1687–1697 (2024).10.1038/s41557-024-01557-2 ↗
20. Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).10.1038/s41587-019-0247-3 ↗
21. Zhu, Y. et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nat. Biomed. Eng. 8, 544–560 (2024).10.1038/s41551-023-01131-0 ↗
22. Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060–2065 (2017).10.1073/pnas.1620874114 ↗
23. Xue, L. et al. High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models. Nat. Commun. 15, 1884 (2024).10.1038/s41467-024-45422-9 ↗
24. Rhym, L. H., Manan, R. S., Koller, A., Stephanie, G. & Anderson, D. G. Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery. Nat. Biomed. Eng. 7, 901–910 (2023).10.1038/s41551-023-01030-4 ↗
25. Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002–1008 (2024).10.1038/s41563-024-01867-3 ↗
26. Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55, 2–12 (2022).10.1021/acs.accounts.1c00544 ↗
27. Qiu, M., Li, Y., Bloomer, H. & Xu, Q. Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing. Acc. Chem. Res. 54, 4001–4011 (2021).10.1021/acs.accounts.1c00500 ↗
28. Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181–12277 (2021).10.1021/acs.chemrev.1c00244 ↗
29. Thalmayr, S. et al. Molecular chameleon carriers for nucleic acid delivery: the sweet spot between lipoplexes and polyplexes. Adv. Mater. 35, 2211105 (2023).10.1002/adma.202211105 ↗
30. Lin, Y. et al. Chemical evolution of amphiphilic xenopeptides for potentiated Cas9 ribonucleoprotein delivery. J. Am. Chem. Soc. 145, 15171–15179 (2023).10.1021/jacs.3c01902 ↗
31. Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955–3960 (2014).10.1073/pnas.1322937111 ↗
32. Cheng, M. H. Y. et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, 2303370 (2023).10.1002/adma.202303370 ↗
33. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).10.1002/anie.201203263 ↗
34. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
35. Tilstra, G. et al. Iterative design of ionizable lipids for intramuscular mRNA delivery. J. Am. Chem. Soc. 145, 2294–2304 (2023).10.1021/jacs.2c10670 ↗
36. Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).10.1073/pnas.2116271119 ↗
37. Fenton, O. S. et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29, 1606944 (2017).10.1002/adma.201606944 ↗
38. Fei, Y. et al. Simplified lipid nanoparticles for tissue- and cell-targeted mRNA delivery facilitate precision tumor therapy in a lung metastasis mouse model. Adv. Mater. 36, 2409812 (2024).10.1002/adma.202409812 ↗
39. Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926–9937 (2022).10.1021/jacs.2c02706 ↗
40. Paunovska, K. et al. A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Lett. 18, 2148–2157 (2018).10.1021/acs.nanolett.8b00432 ↗
41. Whitehead, K. A. et al. In vitro–in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano 6, 6922–6929 (2012).10.1021/nn301922x ↗
42. Huang, P., Deng, H., Wang, C., Zhou, Y. & Chen, X. Cellular trafficking of nanotechnology-mediated mRNA delivery. Adv. Mater. 36, 2307822 (2024).10.1002/adma.202307822 ↗
43. Hashiba, K. et al. Branching ionizable lipids can enhance the stability, fusogenicity, and functional delivery of mRNA. Small Sci. 3, 2200071 (2023).10.1002/smsc.202200071 ↗
44. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
45. Miao, L. et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun. 11, 2424 (2020).10.1038/s41467-020-16248-y ↗
46. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).10.1038/s41586-019-1711-4 ↗
47. Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).10.1126/science.adk9428 ↗
48. Wei, T. et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat. Commun. 14, 7322 (2023).10.1038/s41467-023-42948-2 ↗
49. An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 42, 1526–1537 (2024).10.1038/s41587-023-02078-y ↗
50. Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253–264 (2024).10.1038/s41587-023-01758-z ↗
51. Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402–410 (2022).10.1038/s41587-021-01039-7 ↗
52. Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635–5652.e29 (2021).10.1016/j.cell.2021.09.018 ↗
53. Zou, Q. et al. Photoactivatable base editors for spatiotemporally controlled genome editing in vivo. Biomaterials 302, 122328 (2023).10.1016/j.biomaterials.2023.122328 ↗